TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $22.00 target price on the stock.
TFF Pharmaceuticals Stock Performance
NASDAQ TFFP opened at $0.74 on Friday. The firm has a market capitalization of $25.88 million, a PE ratio of -0.55 and a beta of 1.21. The company has a 50-day simple moving average of $0.89 and a 200-day simple moving average of $2.01. TFF Pharmaceuticals has a one year low of $0.62 and a one year high of $7.70.
Insider Activity at TFF Pharmaceuticals
In other news, CEO Harlan F. Weisman acquired 150,000 shares of the business’s stock in a transaction that occurred on Friday, March 10th. The shares were purchased at an average cost of $0.88 per share, for a total transaction of $132,000.00. Following the transaction, the chief executive officer now directly owns 214,615 shares in the company, valued at approximately $188,861.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 177,000 shares of company stock worth $153,780 in the last ninety days. 4.60% of the stock is owned by insiders.
Institutional Trading of TFF Pharmaceuticals
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
- Get a free copy of the StockNews.com research report on TFF Pharmaceuticals (TFFP)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.